233 related articles for article (PubMed ID: 36439497)
1. Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance.
Robak T; Robak P
Front Oncol; 2022; 12():976374. PubMed ID: 36439497
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
3. [Hairy cell leukemia. An alternative method for the detection of minimal residual disease using flow cytometry].
Bengio R; Narbaitz M; Palacios F; Scolnik M; Sarmiento M
Medicina (B Aires); 2000; 60 Suppl 2():71-6. PubMed ID: 11188936
[TBL] [Abstract][Full Text] [Related]
4. BRAF V600E mutation detection in hairy cell leukemia-utility of archival DNA from bone marrow aspirate/imprint smear and amplification refractory mutation system.
Naseem S; Gupta O; Binota J; Varma N; Varma S; Malhotra P
Mol Biol Rep; 2020 Jun; 47(6):4365-4372. PubMed ID: 32458259
[TBL] [Abstract][Full Text] [Related]
5. Cladribine in hairy cell leukemia.
Belani R; Saven A
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
[TBL] [Abstract][Full Text] [Related]
6. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
Kreitman RJ; Dearden C; Zinzani PL; Delgado J; Robak T; le Coutre PD; Gjertsen BT; Troussard X; Roboz GJ; Karlin L; Gladstone DE; Kuptsova-Clarkson N; Liu S; Patel P; Rotolo F; Mitry E; Pastan I; Giles F;
J Hematol Oncol; 2021 Feb; 14(1):35. PubMed ID: 33627164
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease, its detection and significance in hairy-cell leukemia.
Zák P; Chrobák L; Dĕdic K
Acta Medica (Hradec Kralove); 1999; 42(3):85-8. PubMed ID: 10677893
[TBL] [Abstract][Full Text] [Related]
8. Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Oncologist; 2020 Jan; 25(1):e170-e177. PubMed ID: 31628266
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up.
Kreitman RJ; Tallman MS; Robak T; Coutre S; Wilson WH; Stetler-Stevenson M; FitzGerald DJ; Santiago L; Gao G; Lanasa MC; Pastan I
Blood; 2018 May; 131(21):2331-2334. PubMed ID: 29487070
[TBL] [Abstract][Full Text] [Related]
10. Biology and Treatment of Hairy Cell Leukemia.
Paillassa J; Troussard X
Curr Treat Options Oncol; 2020 Apr; 21(6):44. PubMed ID: 32350628
[TBL] [Abstract][Full Text] [Related]
11. Immunoconjugates and new molecular targets in hairy cell leukemia.
Kreitman RJ
Hematology Am Soc Hematol Educ Program; 2012; 2012():660-6. PubMed ID: 23233649
[TBL] [Abstract][Full Text] [Related]
12. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.
Ravandi F; Kreitman RJ; Tiacci E; Andritsos L; Banerji V; Barrientos JC; Bhat SA; Blachly JS; Broccoli A; Call T; Chihara D; Dearden C; Demeter J; Dietrich S; Else M; Epperla N; Falini B; Forconi F; Gladstone DE; Gozzetti A; Iyengar S; Johnston JB; Jorgensen J; Juliusson G; Lauria F; Lozanski G; Parikh SA; Park JH; Polliack A; Quest G; Robak T; Rogers KA; Saven A; Seymour JF; Tadmor T; Tallman MS; Tam CS; Thompson PA; Troussard X; Zent CS; Zenz T; Zinzani PL; Wörmann B; Rai K; Grever M
Blood Cancer J; 2022 Dec; 12(12):165. PubMed ID: 36509740
[TBL] [Abstract][Full Text] [Related]
13. Hairy cell leukemia: early immunophenotypical detection and quantitative analysis by flow cytometry.
Babusíková O; Tomová A
Neoplasma; 2003; 50(5):350-6. PubMed ID: 14628088
[TBL] [Abstract][Full Text] [Related]
14. Hairy cell leukemia with CCND1/IGH fusion gene and BRAF V600E mutation.
Rahman ZA; Muwalla F; Jiang L; Foran J
Leuk Res Rep; 2020; 13():100197. PubMed ID: 32257795
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia.
Wang XJ; Kim A; Li S
Int J Clin Exp Pathol; 2014; 7(7):4323-8. PubMed ID: 25120816
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
[TBL] [Abstract][Full Text] [Related]
17. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study.
Matutes E; Meeus P; McLennan K; Catovsky D
Br J Haematol; 1997 Aug; 98(2):375-83. PubMed ID: 9266936
[TBL] [Abstract][Full Text] [Related]
18. Development of Recombinant Immunotoxins for Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32756468
[TBL] [Abstract][Full Text] [Related]
19. Hairy cell leukemia: present and future directions.
Kreitman RJ
Leuk Lymphoma; 2019 Dec; 60(12):2869-2879. PubMed ID: 31068044
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues.
Kreitman RJ; Arons E
Blood Rev; 2022 Jan; 51():100888. PubMed ID: 34535326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
